

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Jul 2026

A randomized, two-armed, parallel, double-blind, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-liraglutide (CinnaGen Co., Iran) to innovator liraglutide product (Victoza®, Novo Nordisk, Denmark) in patients with type II diabetes (T2D)

Protocol summary

Study aim

Comparing the efficacy and safety of Cinnagen liraglutide and Novo Nordisk Victoza® in type II diabetes patients

Design

randomized, two-armed, parallel, double-blind, active-controlled, non-inferiority clinical trial of 300 type II diabetes patients

Settings and conduct

2 cities (Tehran and Karaj) and 17 centers will participate in this study. The patients will be included in the study after declaring informed consent and meeting specific inclusion/exclusion criteria. Initially, the patients will be given a randomization code and will be allocated randomly to one of the two intervention groups. The study drugs will be used in exact identical shape, box, and labels so the investigator, the patient, and data analyzer will be completely unaware of the drug which certain patient has received. Subsequently, the patient will be injected daily and Evaluation and clinical examination will be performed in 7 visits and will be monitored for 6 months after the first injection.

Participants/Inclusion and exclusion criteria

Subjects with type 2 diabetes treated for ≥ 3 months with a stable metformin dose of ≥ 1500 mg and at least half the maximum dose of a insulin secretagogues agent; 18–80 years old; $7 \leq \text{HbA1c} \leq 10.5$; BMI: 20–45 Kg/m² and informed consent; no Hypersensitivity to liraglutide or any formulation component, no Insulin treatment during the previous 3 months; Impaired liver or renal function: Uncontrolled hypertension; Malignancy; History or family history of Medullary Thyroid Carcinoma or MEN syndrome type 2; History of pancreatic cancer and pancreatitis; Recent MI; Pregnancy or Previous exposure to exenatide or liraglutide.

Intervention groups

either liraglutide (cinnagen) or victoza group receive 0.6

mg/day subcutaneous liraglutide for a week and then 1.2 mg/day up to 3 weeks and finally 1.8 mg/day to the end of week 26

Main outcome variables

Change in HbA1c after 26 weeks of treatment

General information

Reason for update

Protocol changes: Blood test and antidrug antibody presence evaluating (week 0 week 12 and week 26) HbA1c equal or greater than 7 and equal or smaller than 10.5 18–80 years of age Subjects with type 2 diabetes treated for ≥ 3 months with a stable metformin dose of ≥ 1500 mg and at least half the maximum dose of a sulfonylurea or non-sulfonylurea insulin secretagogues agent (Half of maximum dose) breast-feeding Female who intends to become pregnant during the clinical trial period Dr. Mahsan Seifoddin-Melli Bank Hospital Dr. Mohammad Khaledi- Lolagar Hospital

Acronym

IRCT registration information

IRCT registration number: **IRCT20150303021315N15**

Registration date: **2019-09-13, 1398/06/22**

Registration timing: **registered_while_recruiting**

Last update: **2020-09-29, 1399/07/08**

Update count: **3**

Registration date

2019-09-13, 1398/06/22

Registrant information

Name

Nassim Anjidan

Name of organization / entity

Orchid Pharmed

Country

Iran (Islamic Republic of)

Phone

+98 21 4347 3000

Email address

amini@orchidpharmed.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-06-10, 1398/03/20

Expected recruitment end date

2021-05-02, 1400/02/12

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A randomized, two-armed, parallel, double-blind, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-liraglutide (CinnaGen Co., Iran) to innovator liraglutide product (Victoza®, Novo Nordisk, Denmark) in patients with type II diabetes (T2D)

Public title

Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients with Type II Diabetes

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Subjects with type 2 diabetes treated for ≥ 3 months with a stable metformin dose of ≥ 1500 mg and at least half the maximum dose of a sulfonylurea or non-sulfonylurea insulin secretagogues agent (Half of maximum dose) 18-80 years of age HbA1c equal or greater than 7 and equal or smaller than 10.5 Body mass index (BMI) of 20-45 kg/m²

Exclusion criteria:

Lack of consent for being in the trial and not complying with 26-weeks follow-up period Hypersensitivity to liraglutide or any component of the formulation (excipients include Disodium phosphate dehydrate, Propylene glycol, Phenol, Water for injection) Insulin treatment during the previous 3 months (except short-term treatment for intercurrent illness) Impaired liver function (alanine aminotransferase concentrations equal to or greater than 2.5 times upper normal range). Impaired renal function (eGFR smaller than 60 mL/min/1.73 m²) Uncontrolled hypertension (equal or greater than 160/100 mmHg) Malignancy Using any drugs apart from OGLAs likely to affect glucose concentrations, including androgens, hyperglycemia-associated agents, hypoglycemia-associated agents, MAO inhibitors, quinolone antibiotics, salicylates (Anti-inflammatory dose). Current use of a dipeptidyl peptidase-4 inhibitor (DPP-4i) Treatment with systemic corticosteroids within last three months History or family history of Medullary Thyroid Carcinoma (MTC) Multiple

endocrine neoplasia syndrome type 2 (MEN2) History of pancreatic cancer and pancreatitis History of recent MI, uncontrolled CHF, and unstable Angina within last 3 months History or known case of severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy Pregnancy or breast-feeding Female who intends to become pregnant during the clinical trial period Previous exposure to exenatide or liraglutide.

Age

From **18 years** old to **80 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **300**

Randomization (investigator's opinion)

Randomized

Randomization description

The randomization plan of the patients will be carried out centrally using an R-CRAN software version 3.2.3. Blocks (with the size 2 or 4) will be made using permuted block randomization for a total of 300 patients (1:1 allocation ratio). After randomization procedure, a code will be allocated to each patient that will be used as patient identifier throughout the study. The assigned code will be denoted by 4 initials (corresponding to the first two letters of first name, first two letters of surname) and 4 numbers (center code). Moreover, the described code is followed by study unique identification code consisting of first two letters of the generic name of the investigational product and study phase number, respectively (LI3), and four numbers (corresponding to the randomization number), e.g. ABCD0001LI3-0001. The randomization number will be assigned in a consecutive way.

Blinding (investigator's opinion)

Double blinded

Blinding description

The medication compartment of both Victoza® and test-liraglutide (CinnaGen) will be placed in similar pen-injector containers, in a way that they cannot be differentiated by the appearance. Additionally, The center researcher and the patient are not aware of the drug grouping.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

1

Registry name

ClinicalTrial.gov

Secondary trial Id

NCT03421119

Registration date

2018-02-02, 1396/11/13

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Iran University of Medical Sciences

Street address

Near Milad Tower, Shahid Hemmat Highway

City

Tehran

Province

Tehran

Postal code

1449614535

Approval date

2019-01-23, 1397/11/03

Ethics committee reference number

IR.IUMS.REC.1396.31731

2

Ethics committee

Name of ethics committee

Ethics Committee of Alborz University of Medical Sciences

Street address

Hassan Abad, Karaj, Alborz Province

City

Karaj

Province

Alborz

Postal code

1462364641

Approval date

2019-06-15, 1398/03/25

Ethics committee reference number

IR.ABZUMS.REC.1398.052

Health conditions studied

1

Description of health condition studied

type 2 diabetes

ICD-10 code

E11

ICD-10 code description

Type 2 diabetes mellitus

Primary outcomes

1

Description

Change in HbA1c after 26 weeks of treatment

Timepoint

Screening, baseline, week 12, and week 26

Method of measurement

By High-performance liquid chromatography (HPLC)

Secondary outcomes

1

Description

Percentages of subjects achieving HbA1c < 7.0%

Timepoint

Screening, baseline, week 12, and week 26

Method of measurement

-By High-performance liquid chromatography(HPLC)

2

Description

Percentages of subjects achieving HbA1c ≤ 6.5%

Timepoint

Screening, baseline week 12, and week 26

Method of measurement

By High-performance liquid chromatography(HPLC)

3

Description

Changes in body weight

Timepoint

Screening, baseline week 12, and week 26

Method of measurement

Scales

4

Description

Changes in mean FBS

Timepoint

Baseline, week 12, and week 26

Method of measurement

Laboratory Test

5

Description

Changes in mean PPBS

Timepoint

Baseline, week 12, and week 26

Method of measurement

Laboratory Test

6

Description

Changes in Systolic Blood Pressure

Timepoint

Screening, baseline, week 4, week 8, week 12, and week 26

Method of measurement

Medical examination

7

Description

Changes in Diastolic Blood Pressure

Timepoint

Screening, baseline, week 4, week 8, week 12, and week 26

Method of measurement

Medical examination

8

Description

Changes in Lipid profiles

Timepoint

Baseline, week 12, and week 26

Method of measurement

Laboratory Test

9

Description

Change in Pulse Rate

Timepoint

Screening, baseline, week 4, week 8, week 12, and week 26

Method of measurement

Medical examination

10

Description

Change in eGFR

Timepoint

Screening, baseline, week 12, and week 26

Method of measurement

Laboratory Test

11

Description

Change in ALT

Timepoint

Screening, Baseline, week 12, and week 26

Method of measurement

Laboratory Test

12

Description

Change in liver AST

Timepoint

Baseline, week 12, and week 26

Method of measurement

Laboratory Test

13

Description

Adverse events with special focus on the incidence, severity, and duration of gastrointestinal disturbances, nausea, vomiting, diarrhea; kidney function (BUN, SCr), liver function (ALT, AST, ALP), serum levels of Amylase and Lipase, tachycardia/palpitation, and antibody formation

Timepoint

Screening, baseline, week 4, week 8, week 12, week 16, week 20, and week 26

Method of measurement

evaluation adverse events and adverse drug reaction

14

Description

Change in quality of life

Timepoint

Baseline, week 12 and week 26

Method of measurement

EQ5D questionnaire

15

Description

Medication adherence

Timepoint

Baseline, week 12 and week 26

Method of measurement

Morisky questionnaire

16

Description

Cost-effectiveness

Timepoint

Baseline, week 4, week 8, week 12, week 16, week 20 and week 26

Method of measurement

Cost-effectiveness questionnaire

17

Description

Fear of injection

Timepoint

Baseline, week 12 and week 26

Method of measurement

D-FISQ questionnaire

Intervention groups

1

Description

Liraglutide (produced by CinnaGen Co.) pen-injector (18 mg/3 ml), subcutaneous injection of 0.6 mg every day for one week, followed by a dose of 1.2 mg per day for up to three weeks. Then, 1.8 mg daily subcutaneous injection will be performed until the end of week 26.

Category

2**Description**

Victoza® (produced by Novo Nordisk Company) pen-injector (18 mg/3 ml), subcutaneous injection of 0.6 mg every day for one week, followed by a dose of 1.2 mg per day for up to three weeks. Then, 1.8 mg daily subcutaneous injection will be performed until the end of week 26.

Category

Treatment - Drugs

Recruitment centers1**Recruitment center****Name of recruitment center**

Institute of Endocrinology and Metabolism Research and Training Center

Full name of responsible person

Mohammad Ebrahim Khamseh

Street address

Behafarin ST, Karimkhan AVE, Vali-asr Sq

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8894 5246

Fax

+98 21 8894 5173

Email

m.e.khamseh@gmail.com

2**Recruitment center****Name of recruitment center**

Dr Esteghamati Office

Full name of responsible person

Alireza Esteghamati

Street address

Unit 13, 2nd floor, ebne sina Building, before shariati St, motahhari St

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8841 7918

Fax**Email**

Esteghamati@tums.ac.ir

3**Recruitment center****Name of recruitment center**

Dr Mohajerani Office

Full name of responsible person

Mohammadreza Mohajeri Tehrani

Street address

No.103, Shokr-allah St, In front of Tehran Heart Center, North Kargar Ave

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8802 5450

Email

Mrmohajeri@tums.ac.ir

4**Recruitment center****Name of recruitment center**

Shahid Rajaei Hospital

Full name of responsible person

Zahra Ghaem maghami

Street address

Valiasr Ave, Niayesh Intersection

City

tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 2392 2197

Email

zahra_ghaem2000@yahoo.com

5**Recruitment center****Name of recruitment center**

Dr Monavari Office

Full name of responsible person

Arezou monavari

Street address

No. 11, Bahar Medical building, Shahid taheri Alley, Bahar Ave

City

karaj

Province

Alborz

Postal code

1593748711

Phone

+98 26 3225 6438

Email

Dr_a_mon@yahoo.com

6

Recruitment center

Name of recruitment center

Taban Clinic

Full name of responsible person

Ramin malbousbaf

Street address

No.100, End of Derakhti Blvd, Dadman Blvd, Shahrak-e-Qarb

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 2237 7250

Email

ramin_baf@yahoo.com

7

Recruitment center

Name of recruitment center

Dr Zamanzadeh Office

Full name of responsible person

Mehran Zaman zadeh

Street address

No.10, third floor, Tooran(135) medical building, West hoveyzeh St, North Sohrevardi

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8874 7090

Email

dr_mzamanzadeh@yahoo.com

8

Recruitment center

Name of recruitment center

Dr Hossein Panah Office

Full name of responsible person

Farhad hosein panah

Street address

No. 178, Lower Tehran Clinic, Ghaem Magham Street

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 4425 7406

Email

Farhad.hosseinpanah@gmail.com

9

Recruitment center

Name of recruitment center

Dr Khannakhjavani Office

Full name of responsible person

Manouchehr Khan Nakhjavani

Street address

No. 82, Fajr Street (Jam), Motahhari Street

City

Tehran

Province

Tehran

Postal code

1487474884

Phone

+98 21 8883 0323

Email

nakhjavanim@tums.ac.ir

10

Recruitment center

Name of recruitment center

Personal Office

Full name of responsible person

Amir Kamran Nikoosokhan

Street address

First Floor, No. 17, Shohada Alley, Above Motahhari, Mirzaee Shirazi Street

City

Tehran

Province

Tehran

Postal code

1493846644

Phone

+98 21 8872 8237

Email

amirkamranniko@yahoo.com

11

Recruitment center

Name of recruitment center

Lolagar Hospital

Full name of responsible person

Zahra Banazadeh

Street address

South Khosh street, diabetes st

City

Tehran

Province

Tehran

Postal code

1492374646

Phone

+98 21 6683 5000

Email

zbanazadeh01@gmail.com

12

Recruitment center

Name of recruitment center

Personal Office

Full name of responsible person

Hassan Ganjizadeh

Street address

No. 52, Fathi Shaghaghi Street, Yousef Abad

City

Tehran

Province

Tehran

Postal code

1539474621

Phone

+98 21 8810 9722

Email

hganjizadeh@gmail.com

13

Recruitment center

Name of recruitment center

Shohadaye Yaft Abad Hospital

Full name of responsible person

Mitra Najafipour Moghadam

Street address

South Al Ghadir Boulevard, Al Ghadir Square, Moallem Square,

City

Tehran

Province

Tehran

Postal code

1436824005

Phone

+98 21 6678 3120

Email

Mnajafipm@gmail.com

14

Recruitment center

Name of recruitment center

Firouz Abadi Hospital

Full name of responsible person

Fatemeh Tajik Rostami

Street address

Fadaiyane Eslam Street, Shahre rey

City

Tehran

Province

Tehran

Postal code

1455457210

Phone

+98 21 5104 8000

Email

faatajik@yahoo.com

15

Recruitment center

Name of recruitment center

Shariat Razavi Hospital

Full name of responsible person

Hedayat Allah Rezvanfar

Street address

Shahid Abdollahi Street, South Mehr Abad

City

Tehran

Province

Tehran

Postal code

1465820317

Phone

+98 21 6687 6031

Email

hedrezvanfar@gmail.com

16

Recruitment center

Name of recruitment center

Personal Office

Full name of responsible person

Habib Moazami Goudarzi

Street address

Ehsan Building, opposite Ghaem Hospital, Student Boulevard

City

Karaj

Province

Alborz

Postal code

1450312891

Phone

+98 26 3271 8706

Email

Habibmoazami@yahoo.com

17

Recruitment center

Name of recruitment center

Melli Bank Hospital

Full name of responsible person

Mahsan Seifoddin

Street address

Ferdowsi St., Central Office Building, Bank Melli Hospital

City

Tehran

Province

Tehran

Postal code

3376311359

Phone

+98 21 6142 0000

Email

mseifoddin40@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

CinnaGen Company

Full name of responsible person

haleh Hamedifar

Street address

CinnaGen research and production Company. Simin
Dasht Industrial Park, Karaj, Alborz, Iran

City

Karaj

Province

Alborz

Postal code

6670337 263 98

Phone

+98 26 3667 0334

Email

cinnagen@cinnagen.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

CinnaGen Company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries

Contact**Name of organization / entity**

Orchid Pharmed Co.

Full name of responsible person

Nassim Anjidani

Position

Pharmacist (PharmD), Medical Manager

Latest degree

Medical doctor

Other areas of specialty/work

Medical Pharmacy

Street address

No. 42, Atar St, Attar Sq

City

Tehran

Province

Tehran

Postal code

1994766411

Phone

+98 21 4347 3000

Email

anjidani.n@orchidpharmed.com

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Institute of Endocrinology and Metabolism Research
and Training Center

Full name of responsible person

Mohammad Ebrahim Khamseh

Position

Iran university of medical science prof- coordinating
investigator

Latest degree

Subspecialist

Other areas of specialty/work

General Practitioner

Street address

Behafarin ST, Karimkhan AVE, Vali-asr Sq

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8894 5246

Email

m.e.khamseh@gmail.com

Person responsible for updating data

Contact**Name of organization / entity**

OrchidPharmed Co.

Full name of responsible person

Nassim Anjidani

Position

Pharm.D./Medical Department Manager

Latest degree

Medical doctor

Other areas of specialty/work

Medical Pharmacy

Street address

No. 42, Atar St, Attar Sq

City

Tehran

Province

Tehran

Postal code

1994766411

Phone

+98 21 4347 3000

Email

anjidani.n@orchidpharmed.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available